The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

The future of clinical research depends on people just as much as strong systems and processes. Learn what makes great ...

Dermatology in the near future will be characterized by digitally enabled, patient-centred research that reaches people where ...

The world of medicine has taken a significant leap forward with the first AI-generated drug entering clinical trials. This breakthrough has the potential to revolutionize drug discovery, transforming ...

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers ...

The U.S. Food and Drug Administration and the European Medicines Agency jointly issued principles for safe and responsible ...

Jo Varshney, PhD, DVM, discusses how VeriSIM Life’s innovative approach leverages artificial intelligence and multispecies ...

FDA proposes framework clinical trial designs to guide Bayesian methods, improving efficiency in drug development for rare and pediatric conditions.

The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...

On Wednesday, the U.S. Food and Drug Administration (FDA) published three new draft guidances that aim to offer greater clarity to sponsors of cell and gene therapies (CGTs) on issues related to ...

Funding backs a human-first approach to drug safety and efficacy, reducing reliance on animal testing and accelerating therapies for patients. NEW HAVEN, CT / ACCESS Newswire / December 5, 2025 / ...

Funding backs a human-first approach to drug safety and efficacy, reducing reliance on animal testing and accelerating therapies for patients. Revalia will lead the effort to build advanced AI-driven ...